 | • レポートコード：MRC2-11QY11420 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、130ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はCNS治療薬のグローバル市場について調査・分析したレポートです。種類別（神経変性疾患、気分障害、統合失調症、自閉症、うつ病）市場規模、用途別（病院、クリニック、家庭、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別CNS治療薬の競争状況、市場シェア ・世界のCNS治療薬市場：種類別市場規模 2015年-2020年（神経変性疾患、気分障害、統合失調症、自閉症、うつ病） ・世界のCNS治療薬市場：種類別市場規模予測 2021年-2026年（神経変性疾患、気分障害、統合失調症、自閉症、うつ病） ・世界のCNS治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、家庭、その他） ・世界のCNS治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、家庭、その他） ・北米のCNS治療薬市場分析：米国、カナダ ・ヨーロッパのCNS治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのCNS治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のCNS治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのCNS治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Janssen Pharmaceuticals、Allergan、Lundbeck、Teva、Camber Pharmaceuticals、Zhejiang Haisen Pharmaceutical、Jewim Pharmaceutical、Cipla、Merck Sharp & Dohme Corp.、Eli Lilly、GlaxoSmithKline、Novartis、LUPIN、ZYDUS PHARMS、Biogen、Otsuka Pharmaceutical、Astra Zeneca、Takeda ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).
Mental health segment accounted for the largest market share in 2016. It is expected to retain its dominance over the forecast period owing to developing therapeutic options for mental diseases such as personality disorders and binge eating disorders. This segment is followed by degenerative disorders segment. There is growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and nongovernment organizations, such as Alzheimer’s and Related Disorders Society of India. These organizations conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental disorders.
Market Analysis and Insights: Global CNS Therapeutics Market
The global CNS Therapeutics market size is projected to reach US$ 80250 million by 2026, from US$ 76300 million in 2020, at a CAGR of 4.8%% during 2021-2026.
Global CNS Therapeutics Scope and Market Size
CNS Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global CNS Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Janssen Pharmaceuticals
Allergan
Lundbeck
Teva
Camber Pharmaceuticals
Zhejiang Haisen Pharmaceutical
Jewim Pharmaceutical
Cipla
Merck Sharp & Dohme Corp.
Eli Lilly
GlaxoSmithKline
Novartis
LUPIN
ZYDUS PHARMS
Biogen
Otsuka Pharmaceutical
Astra Zeneca
Takeda
Market segment by Type, the product can be split into
Neurodegenerative Diseases
Mood Disorders
Schizophrenia
Autism
Depression
Market segment by Application, split into
Hospital Use
Clinic Use
Household
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by CNS Therapeutics Revenue
1.4 Market by Type
1.4.1 Global CNS Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Neurodegenerative Diseases
1.4.3 Mood Disorders
1.4.4 Schizophrenia
1.4.5 Autism
1.4.6 Depression
1.5 Market by Application
1.5.1 Global CNS Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospital Use
1.5.3 Clinic Use
1.5.4 Household
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global CNS Therapeutics Market Perspective (2015-2026)
2.2 Global CNS Therapeutics Growth Trends by Regions
2.2.1 CNS Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 CNS Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 CNS Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 CNS Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key CNS Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top CNS Therapeutics Players by Market Size
3.1.1 Global Top CNS Therapeutics Players by Revenue (2015-2020)
3.1.2 Global CNS Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global CNS Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global CNS Therapeutics Market Concentration Ratio
3.2.1 Global CNS Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by CNS Therapeutics Revenue in 2019
3.3 CNS Therapeutics Key Players Head office and Area Served
3.4 Key Players CNS Therapeutics Product Solution and Service
3.5 Date of Enter into CNS Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global CNS Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global CNS Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global CNS Therapeutics Market Size by Application (2015-2020)
5.2 Global CNS Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America CNS Therapeutics Market Size (2015-2020)
6.2 CNS Therapeutics Key Players in North America (2019-2020)
6.3 North America CNS Therapeutics Market Size by Type (2015-2020)
6.4 North America CNS Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe CNS Therapeutics Market Size (2015-2020)
7.2 CNS Therapeutics Key Players in Europe (2019-2020)
7.3 Europe CNS Therapeutics Market Size by Type (2015-2020)
7.4 Europe CNS Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China CNS Therapeutics Market Size (2015-2020)
8.2 CNS Therapeutics Key Players in China (2019-2020)
8.3 China CNS Therapeutics Market Size by Type (2015-2020)
8.4 China CNS Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan CNS Therapeutics Market Size (2015-2020)
9.2 CNS Therapeutics Key Players in Japan (2019-2020)
9.3 Japan CNS Therapeutics Market Size by Type (2015-2020)
9.4 Japan CNS Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia CNS Therapeutics Market Size (2015-2020)
10.2 CNS Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia CNS Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia CNS Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India CNS Therapeutics Market Size (2015-2020)
11.2 CNS Therapeutics Key Players in India (2019-2020)
11.3 India CNS Therapeutics Market Size by Type (2015-2020)
11.4 India CNS Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America CNS Therapeutics Market Size (2015-2020)
12.2 CNS Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America CNS Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America CNS Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer CNS Therapeutics Introduction
13.1.4 Pfizer Revenue in CNS Therapeutics Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Janssen Pharmaceuticals
13.2.1 Janssen Pharmaceuticals Company Details
13.2.2 Janssen Pharmaceuticals Business Overview
13.2.3 Janssen Pharmaceuticals CNS Therapeutics Introduction
13.2.4 Janssen Pharmaceuticals Revenue in CNS Therapeutics Business (2015-2020)
13.2.5 Janssen Pharmaceuticals Recent Development
13.3 Allergan
13.3.1 Allergan Company Details
13.3.2 Allergan Business Overview
13.3.3 Allergan CNS Therapeutics Introduction
13.3.4 Allergan Revenue in CNS Therapeutics Business (2015-2020)
13.3.5 Allergan Recent Development
13.4 Lundbeck
13.4.1 Lundbeck Company Details
13.4.2 Lundbeck Business Overview
13.4.3 Lundbeck CNS Therapeutics Introduction
13.4.4 Lundbeck Revenue in CNS Therapeutics Business (2015-2020)
13.4.5 Lundbeck Recent Development
13.5 Teva
13.5.1 Teva Company Details
13.5.2 Teva Business Overview
13.5.3 Teva CNS Therapeutics Introduction
13.5.4 Teva Revenue in CNS Therapeutics Business (2015-2020)
13.5.5 Teva Recent Development
13.6 Camber Pharmaceuticals
13.6.1 Camber Pharmaceuticals Company Details
13.6.2 Camber Pharmaceuticals Business Overview
13.6.3 Camber Pharmaceuticals CNS Therapeutics Introduction
13.6.4 Camber Pharmaceuticals Revenue in CNS Therapeutics Business (2015-2020)
13.6.5 Camber Pharmaceuticals Recent Development
13.7 Zhejiang Haisen Pharmaceutical
13.7.1 Zhejiang Haisen Pharmaceutical Company Details
13.7.2 Zhejiang Haisen Pharmaceutical Business Overview
13.7.3 Zhejiang Haisen Pharmaceutical CNS Therapeutics Introduction
13.7.4 Zhejiang Haisen Pharmaceutical Revenue in CNS Therapeutics Business (2015-2020)
13.7.5 Zhejiang Haisen Pharmaceutical Recent Development
13.8 Jewim Pharmaceutical
13.8.1 Jewim Pharmaceutical Company Details
13.8.2 Jewim Pharmaceutical Business Overview
13.8.3 Jewim Pharmaceutical CNS Therapeutics Introduction
13.8.4 Jewim Pharmaceutical Revenue in CNS Therapeutics Business (2015-2020)
13.8.5 Jewim Pharmaceutical Recent Development
13.9 Cipla
13.9.1 Cipla Company Details
13.9.2 Cipla Business Overview
13.9.3 Cipla CNS Therapeutics Introduction
13.9.4 Cipla Revenue in CNS Therapeutics Business (2015-2020)
13.9.5 Cipla Recent Development
13.10 Merck Sharp & Dohme Corp.
13.10.1 Merck Sharp & Dohme Corp. Company Details
13.10.2 Merck Sharp & Dohme Corp. Business Overview
13.10.3 Merck Sharp & Dohme Corp. CNS Therapeutics Introduction
13.10.4 Merck Sharp & Dohme Corp. Revenue in CNS Therapeutics Business (2015-2020)
13.10.5 Merck Sharp & Dohme Corp. Recent Development
13.11 Eli Lilly
10.11.1 Eli Lilly Company Details
10.11.2 Eli Lilly Business Overview
10.11.3 Eli Lilly CNS Therapeutics Introduction
10.11.4 Eli Lilly Revenue in CNS Therapeutics Business (2015-2020)
10.11.5 Eli Lilly Recent Development
13.12 GlaxoSmithKline
10.12.1 GlaxoSmithKline Company Details
10.12.2 GlaxoSmithKline Business Overview
10.12.3 GlaxoSmithKline CNS Therapeutics Introduction
10.12.4 GlaxoSmithKline Revenue in CNS Therapeutics Business (2015-2020)
10.12.5 GlaxoSmithKline Recent Development
13.13 Novartis
10.13.1 Novartis Company Details
10.13.2 Novartis Business Overview
10.13.3 Novartis CNS Therapeutics Introduction
10.13.4 Novartis Revenue in CNS Therapeutics Business (2015-2020)
10.13.5 Novartis Recent Development
13.14 LUPIN
10.14.1 LUPIN Company Details
10.14.2 LUPIN Business Overview
10.14.3 LUPIN CNS Therapeutics Introduction
10.14.4 LUPIN Revenue in CNS Therapeutics Business (2015-2020)
10.14.5 LUPIN Recent Development
13.15 ZYDUS PHARMS
10.15.1 ZYDUS PHARMS Company Details
10.15.2 ZYDUS PHARMS Business Overview
10.15.3 ZYDUS PHARMS CNS Therapeutics Introduction
10.15.4 ZYDUS PHARMS Revenue in CNS Therapeutics Business (2015-2020)
10.15.5 ZYDUS PHARMS Recent Development
13.16 Biogen
10.16.1 Biogen Company Details
10.16.2 Biogen Business Overview
10.16.3 Biogen CNS Therapeutics Introduction
10.16.4 Biogen Revenue in CNS Therapeutics Business (2015-2020)
10.16.5 Biogen Recent Development
13.17 Otsuka Pharmaceutical
10.17.1 Otsuka Pharmaceutical Company Details
10.17.2 Otsuka Pharmaceutical Business Overview
10.17.3 Otsuka Pharmaceutical CNS Therapeutics Introduction
10.17.4 Otsuka Pharmaceutical Revenue in CNS Therapeutics Business (2015-2020)
10.17.5 Otsuka Pharmaceutical Recent Development
13.18 Astra Zeneca
10.18.1 Astra Zeneca Company Details
10.18.2 Astra Zeneca Business Overview
10.18.3 Astra Zeneca CNS Therapeutics Introduction
10.18.4 Astra Zeneca Revenue in CNS Therapeutics Business (2015-2020)
10.18.5 Astra Zeneca Recent Development
13.19 Takeda
10.19.1 Takeda Company Details
10.19.2 Takeda Business Overview
10.19.3 Takeda CNS Therapeutics Introduction
10.19.4 Takeda Revenue in CNS Therapeutics Business (2015-2020)
10.19.5 Takeda Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. CNS Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by CNS Therapeutics Revenue
Table 3. Ranking of Global Top CNS Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global CNS Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Neurodegenerative Diseases
Table 6. Key Players of Mood Disorders
Table 7. Key Players of Schizophrenia
Table 8. Key Players of Autism
Table 9. Key Players of Depression
Table 10. Global CNS Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global CNS Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global CNS Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global CNS Therapeutics Market Share by Regions (2015-2020)
Table 14. Global CNS Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global CNS Therapeutics Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. CNS Therapeutics Market Growth Strategy
Table 20. Main Points Interviewed from Key CNS Therapeutics Players
Table 21. Global CNS Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 22. Global CNS Therapeutics Market Share by Players (2015-2020)
Table 23. Global Top CNS Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CNS Therapeutics as of 2019)
Table 24. Global CNS Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players CNS Therapeutics Product Solution and Service
Table 27. Date of Enter into CNS Therapeutics Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global CNS Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 30. Global CNS Therapeutics Market Size Share by Type (2015-2020)
Table 31. Global CNS Therapeutics Revenue Market Share by Type (2021-2026)
Table 32. Global CNS Therapeutics Market Size Share by Application (2015-2020)
Table 33. Global CNS Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 34. Global CNS Therapeutics Market Size Share by Application (2021-2026)
Table 35. North America Key Players CNS Therapeutics Revenue (2019-2020) (Million US$)
Table 36. North America Key Players CNS Therapeutics Market Share (2019-2020)
Table 37. North America CNS Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 38. North America CNS Therapeutics Market Share by Type (2015-2020)
Table 39. North America CNS Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 40. North America CNS Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Key Players CNS Therapeutics Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players CNS Therapeutics Market Share (2019-2020)
Table 43. Europe CNS Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 44. Europe CNS Therapeutics Market Share by Type (2015-2020)
Table 45. Europe CNS Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 46. Europe CNS Therapeutics Market Share by Application (2015-2020)
Table 47. China Key Players CNS Therapeutics Revenue (2019-2020) (Million US$)
Table 48. China Key Players CNS Therapeutics Market Share (2019-2020)
Table 49. China CNS Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 50. China CNS Therapeutics Market Share by Type (2015-2020)
Table 51. China CNS Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 52. China CNS Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Key Players CNS Therapeutics Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players CNS Therapeutics Market Share (2019-2020)
Table 55. Japan CNS Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 56. Japan CNS Therapeutics Market Share by Type (2015-2020)
Table 57. Japan CNS Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 58. Japan CNS Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players CNS Therapeutics Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players CNS Therapeutics Market Share (2019-2020)
Table 61. Southeast Asia CNS Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia CNS Therapeutics Market Share by Type (2015-2020)
Table 63. Southeast Asia CNS Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia CNS Therapeutics Market Share by Application (2015-2020)
Table 65. India Key Players CNS Therapeutics Revenue (2019-2020) (Million US$)
Table 66. India Key Players CNS Therapeutics Market Share (2019-2020)
Table 67. India CNS Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 68. India CNS Therapeutics Market Share by Type (2015-2020)
Table 69. India CNS Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 70. India CNS Therapeutics Market Share by Application (2015-2020)
Table 71. Central & South America Key Players CNS Therapeutics Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players CNS Therapeutics Market Share (2019-2020)
Table 73. Central & South America CNS Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America CNS Therapeutics Market Share by Type (2015-2020)
Table 75. Central & South America CNS Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America CNS Therapeutics Market Share by Application (2015-2020)
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Product
Table 80. Pfizer Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 81. Pfizer Recent Development
Table 82. Janssen Pharmaceuticals Company Details
Table 83. Janssen Pharmaceuticals Business Overview
Table 84. Janssen Pharmaceuticals Product
Table 85. Janssen Pharmaceuticals Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 86. Janssen Pharmaceuticals Recent Development
Table 87. Allergan Company Details
Table 88. Allergan Business Overview
Table 89. Allergan Product
Table 90. Allergan Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 91. Allergan Recent Development
Table 92. Lundbeck Company Details
Table 93. Lundbeck Business Overview
Table 94. Lundbeck Product
Table 95. Lundbeck Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 96. Lundbeck Recent Development
Table 97. Teva Company Details
Table 98. Teva Business Overview
Table 99. Teva Product
Table 100. Teva Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 101. Teva Recent Development
Table 102. Camber Pharmaceuticals Company Details
Table 103. Camber Pharmaceuticals Business Overview
Table 104. Camber Pharmaceuticals Product
Table 105. Camber Pharmaceuticals Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 106. Camber Pharmaceuticals Recent Development
Table 107. Zhejiang Haisen Pharmaceutical Company Details
Table 108. Zhejiang Haisen Pharmaceutical Business Overview
Table 109. Zhejiang Haisen Pharmaceutical Product
Table 110. Zhejiang Haisen Pharmaceutical Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 111. Zhejiang Haisen Pharmaceutical Recent Development
Table 112. Jewim Pharmaceutical Business Overview
Table 113. Jewim Pharmaceutical Product
Table 114. Jewim Pharmaceutical Company Details
Table 115. Jewim Pharmaceutical Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 116. Jewim Pharmaceutical Recent Development
Table 117. Cipla Company Details
Table 118. Cipla Business Overview
Table 119. Cipla Product
Table 120. Cipla Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 121. Cipla Recent Development
Table 122. Merck Sharp & Dohme Corp. Company Details
Table 123. Merck Sharp & Dohme Corp. Business Overview
Table 124. Merck Sharp & Dohme Corp. Product
Table 125. Merck Sharp & Dohme Corp. Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 126. Merck Sharp & Dohme Corp. Recent Development
Table 127. Eli Lilly Company Details
Table 128. Eli Lilly Business Overview
Table 129. Eli Lilly Product
Table 130. Eli Lilly Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 131. Eli Lilly Recent Development
Table 132. GlaxoSmithKline Company Details
Table 133. GlaxoSmithKline Business Overview
Table 134. GlaxoSmithKline Product
Table 135. GlaxoSmithKline Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 136. GlaxoSmithKline Recent Development
Table 137. Novartis Company Details
Table 138. Novartis Business Overview
Table 139. Novartis Product
Table 140. Novartis Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 141. Novartis Recent Development
Table 142. LUPIN Company Details
Table 143. LUPIN Business Overview
Table 144. LUPIN Product
Table 145. LUPIN Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 146. LUPIN Recent Development
Table 147. ZYDUS PHARMS Company Details
Table 148. ZYDUS PHARMS Business Overview
Table 149. ZYDUS PHARMS Product
Table 150. ZYDUS PHARMS Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 151. ZYDUS PHARMS Recent Development
Table 152. Biogen Company Details
Table 153. Biogen Business Overview
Table 154. Biogen Product
Table 155. Biogen Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 156. Biogen Recent Development
Table 157. Otsuka Pharmaceutical Company Details
Table 158. Otsuka Pharmaceutical Business Overview
Table 159. Otsuka Pharmaceutical Product
Table 160. Otsuka Pharmaceutical Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 161. Otsuka Pharmaceutical Recent Development
Table 162. Astra Zeneca Company Details
Table 163. Astra Zeneca Business Overview
Table 164. Astra Zeneca Product
Table 165. Astra Zeneca Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 166. Astra Zeneca Recent Development
Table 167. Takeda Company Details
Table 168. Takeda Business Overview
Table 169. Takeda Product
Table 170. Takeda Revenue in CNS Therapeutics Business (2015-2020) (Million US$)
Table 171. Takeda Recent Development
Table 172. Research Programs/Design for This Report
Table 173. Key Data Information from Secondary Sources
Table 174. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CNS Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Neurodegenerative Diseases Features
Figure 3. Mood Disorders Features
Figure 4. Schizophrenia Features
Figure 5. Autism Features
Figure 6. Depression Features
Figure 7. Global CNS Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Hospital Use Case Studies
Figure 9. Clinic Use Case Studies
Figure 10. Household Case Studies
Figure 11. Other Case Studies
Figure 12. CNS Therapeutics Report Years Considered
Figure 13. Global CNS Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global CNS Therapeutics Market Share by Regions: 2020 VS 2026
Figure 15. Global CNS Therapeutics Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global CNS Therapeutics Market Share by Players in 2019
Figure 18. Global Top CNS Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CNS Therapeutics as of 2019
Figure 19. The Top 10 and 5 Players Market Share by CNS Therapeutics Revenue in 2019
Figure 20. North America CNS Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe CNS Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China CNS Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan CNS Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia CNS Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India CNS Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America CNS Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
産後うつ病治療薬の世界市場（～2026年） Postpartum depression is a prevalent disorder affecting many women of reproductive age. Mood stabilizing medications reduce the risk of postpartum bipolar depression relapse but no randomized controlled trials have examined their use in the acute or prophylactic treatment of postpartum bipolar depre…- 代謝障害治療薬の世界市場（～2026年） Metabolic Disorders Therapeutics is a drug used to treat the symptoms of metabolic disorders caused by a variety of causes. Due to the increasing pressure of modern life and the spread of unhealthy lifestyles, the global metabolic disorder treatment market will continue to grow strongly during the f…
- ペプチド胃腸障害治療薬の世界市場（～2026年） Gastrointestinal disorders refer to diseases involving the gastrointestinal tract, namely the esophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, gallbladder, and pancreas. Market Analysis and Insights: Global Peptide Based Gastrointesti…
- 子宮疾患治療薬の世界市場（～2026年） Uterus is the muscle organ in female reproductive system, which plays a great role in female reproduction and fetal development. The incidence of uterine diseases is also very high, so the treatment of uterine diseases is particularly important. Market Analysis and Insights: Global Uterine Diseases …
- リソソーム蓄積症（LSD）治療薬の世界市場（～2026年） Lysosomal storage disorders is a group of genetic metabolic diseases caused by enzyme deficiencies in various body cells. The Gaucher's Diseases indication segment is expected to be the most dominant segment in global lysosomal storage diseases therapeutics market. Market Analysis and Insights: Glob…